Agiko

Agiko is a biotechnology company pioneering the field of epigenetic reprogramming to reverse age-related cellular decline and treat chronic diseases. Co-founded by Dr. David Sinclair and Dr. Noah Davidsohn, the company utilizes gene therapy to deliver specific transcription factors that reset the cellular epigenome to a more youthful state. This rejuvenation approach aims to restore lost function in tissues affected by aging, with an initial focus on ophthalmology and neurodegenerative conditions. By targeting the underlying drivers of aging rather than individual symptoms, Agiko seeks to develop a new class of regenerative medicines that can restore vision and promote systemic health. The company operates as part of the Life Biosciences ecosystem, leveraging advanced viral vector delivery systems.